← Back to headlines
ProQR Receives "Buy" Rating from Bank of America on RNA-Editing Platform
ProQR Therapeutics has been upgraded to a "buy" rating by Bank of America, citing the potential of its RNA-editing platform.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
